智通财经网·2026-02-13 13:53Core Insights - Eli Lilly (LLY.US) is preparing inventory for its experimental oral weight loss drug orforglipron, awaiting a potential FDA approval decision in the coming months [1] - The company reported a pre-market inventory value of $1.5 billion related to orforglipron as of December 31, 2025, up from $548.1 million a year earlier [1] - Orforglipron has received a priority review voucher from the FDA and is expected to gain regulatory approval in Q2 2026 for use in overweight or obese adults [1] Group 1: Clinical Trial Results - In the Phase 3 clinical trial ACHIEVE-1, orforglipron demonstrated a reduction in HbA1c levels by an average of 1.3% to 1.6% in adult patients with type 2 diabetes [2] - Significant weight loss of nearly 8% was observed in the high-dose group by week 40, with the drug administered once daily at doses of 3 mg, 12 mg, and 36 mg [2] - Only the 12 mg and 36 mg dosage groups showed clinically meaningful and statistically significant weight loss compared to placebo [2] Group 2: Competitive Landscape - Novo Nordisk (NVO.US) has established a lead in the oral weight loss drug market with its Wegovy product, which was launched in early January and has over 240,000 patients in the U.S. [3] - The company plans to increase investment in Ireland to produce the oral version of Wegovy for markets outside the U.S. [2] - Despite intensifying price competition in the weight loss drug market, Novo Nordisk aims to leverage its oral medication to regain market dominance and close the gap with Eli Lilly [3]